Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique acces.

Business Wire • Oct 27, 2026

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company's Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant.

Business Wire • Oct 26, 2026

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026.

Business Wire • Oct 20, 2026

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.

Zacks Investment Research • Oct 19, 2026

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.

Zacks Investment Research • Oct 16, 2026

Why Healthcare Stocks Are Hot When the AI Trade Runs Cold

Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.

Barrons • Oct 15, 2026

3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge

As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.

Zacks Investment Research • Oct 15, 2026

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.

Zacks Investment Research • Oct 2, 2026

Corcept Announces Planned Leadership Transition

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company's Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October.

Business Wire • Sep 23, 2026

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

Zacks Investment Research • Sep 21, 2026